King's College Hospital
London, United Kingdom
Location status: Recruiting
NCT Number: NCT06572215
This is a feasibility study to assess new, more practical ways of measuring renal reserve.
Interested in participating?
Request Info40 year and older
All sexes
Observational
London, United Kingdom
Location status: Recruiting
Quantification of glomerular filtration rate (GFR) over time is the standard assessment of kidney function. In clinical practice, the endogenous marker, 'serum creatinine' concentration, is used as a static assessment of kidney function to estimate GFR. However, serum creatinine fails to increase until at least 50% of kidney tissue is lost,[2] thus is an inadequate indicator of early CKD.
GFR like many other physiological processes is not static and augments temporarily to stimuli such as exercise and protein intake, by up to 25% from baseline in healthy individuals.[3] Similar to cardiac function stress tests which predict adverse outcomes, inability to respond to renal stressors or 'reduced renal reserve' has been demonstrated to occur prior to development of CKD (e.g. in patients with diabetes and previous acute kidney injury (AKI)) and is associated with vulnerability to future AKI, despite the presence of apparently normal kidney function measured by serum creatinine concentration.[4] Renal reserve is lost with progressive CKD,[4] and has also been demonstrated to relate to severity of histological lesions.[5]
Current measurements of renal reserve (stimulated increase in GFR due to augmented renal blood flow above basal fasting values) involve administration of a compound that is freely filtered by the glomerulus, unaffected by tubular function and is physiologically inert, with assessment before and after an oral protein load or amino acid infusion which induces arterial vasodilation, increasing renal blood flow and GFR
The study proposes a comparison of two novel methods of 'dynamic renal function testing' with renal reserve testing.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion:
Exclusion:
On Day 3 to 16, participants will take 10mg dapaglifozin (SGLT-2 inhibitor) orally once daily.
Time frame: 2 hours
Contact information is provided by the study sponsor or research team.
King's College Hospital NHS Trust
Other
Acronym: DYNAMO
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05173714
Body Weight, Chronic Disease
Stanford, California, United States
View Trial DetailsNCT06810622
Bronchial Diseases, Bronchiolitis
Denver, Colorado, United States
View Trial DetailsNCT06738394
Chronic Disease, Chronic Kidney Diseases
Winston-Salem, North Carolina, United States
View Trial DetailsNCT06051058
Cardiovascular Diseases, Chronic Disease
Boston, Massachusetts, United States
View Trial Details